scholarly journals Current treatment and future directions in the management of anal cancer

2021 ◽  
Author(s):  
Leila T. Tchelebi ◽  
Cathy Eng ◽  
Craig A. Messick ◽  
Theodore S. Hong ◽  
Ethan B. Ludmir ◽  
...  
Keyword(s):  
Anal Cancer ◽  
Current Treatment ◽  
Future Directions

scholarly journals Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions

Biomedicines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 319
Author(s):  
Christian Ogasawara ◽  
Brandon D. Philbrick ◽  
D. Cory Adamson
Keyword(s):  
Central Nervous System ◽  
Current Treatment ◽  
Intracranial Tumor ◽  
Benign Tumors ◽  
Molecular Characteristics ◽  
Total Resection ◽  
Future Directions ◽  
Prediction Of Prognosis ◽  
Potential Use ◽  
Radiotherapy Treatment

Meningiomas are the most common intracranial tumor, making up more than a third of all primary central nervous system (CNS) tumors. They are mostly benign tumors that can be observed or preferentially treated with gross total resection that provides good outcomes. Meningiomas with complicated histology or in compromising locations has proved to be a challenge in treating and predicting prognostic outcomes. Advances in genomics and molecular characteristics of meningiomas have uncovered potential use for more accurate grading and prediction of prognosis and recurrence. With the study and detection of genomic aberrancies, specific biologic targets are now being trialed for possible management of meningiomas that are not responsive to standard surgery and radiotherapy treatment. This review summarizes current epidemiology, etiology, molecular characteristics, diagnosis, treatments, and current treatment trials.

Review on the current treatment status of vein of Galen malformations and future directions in research and treatment

2021 ◽  
pp. 1-22
Author(s):  
Panagiotis Primikiris ◽  
Georgios Hadjigeorgiou ◽  
Maria Tsamopoulou ◽  
Alessandra Biondi ◽  
Christina Iosif
Keyword(s):  
Current Treatment ◽  
Vein Of Galen ◽  
Future Directions ◽  
Treatment Status

scholarly journals Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy

Biomedicines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 9 ◽  
Author(s):  
Andrei A. Deviatkin ◽  
Yulia A. Vakulenko ◽  
Ludmila V. Akhmadishina ◽  
Vadim V. Tarasov ◽  
Marina I. Beloukhova ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Gene Therapy ◽  
Immune Suppression ◽  
Biological Treatment ◽  
Current Treatment ◽  
Joint Disease ◽  
Inflammatory Joint Disease ◽  
Future Directions ◽  
Nonviral Delivery ◽  
Novel Targets

Rheumatoid arthritis (RA) is a systemic inflammatory joint disease affecting about 1% of the population worldwide. Current treatment approaches do not ensure a cure for every patient. Moreover, classical regimens are based on nontargeted systemic immune suppression and have significant side effects. Biological treatment has advanced considerably but efficacy and specificity issues remain. Gene therapy is one of the potential future directions for RA therapy, which is rapidly developing. Several gene therapy trials done so far have been of moderate success, but experimental and genetics studies have yielded novel targets. As a result, the arsenal of gene therapy tools keeps growing. Currently, both viral and nonviral delivery systems are used for RA therapy. Herein, we review recent approaches for RA gene therapy.

Early-Onset Scoliosis: A Review of History, Current Treatment, and Future Directions

PEDIATRICS ◽  
2015 ◽  
Vol 137 (1) ◽  
pp. e20150709 ◽  
Author(s):  
Scott Yang ◽  
Lindsay M Andras ◽  
Gregory J Redding ◽  
David L Skaggs
Keyword(s):  
Early Onset ◽  
Current Treatment ◽  
Early Onset Scoliosis ◽  
Future Directions

Multiple Sclerosis

2017 ◽  
Author(s):  
Pavan Bhargava ◽  
Peter A. Calabresi
Keyword(s):  
Multiple Sclerosis ◽  
Immunosuppressive Agents ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Phase 2 ◽  
Future Directions ◽  
Disease Modifying Therapies ◽  
Future Challenges ◽  
Brain And Spinal Cord ◽  
The Brain

Multiple sclerosis is a chronic demyelinating neurological disorder of the brain and spinal cord, with both inflammatory and degenerative components. Current treatment strategies utilize immunomodulatory and immunosuppressive agents to reduce the inflammatory disease activity and retard accumulation of disability. Future challenges for treatment include identifying agents that will promote remyelination and axonal protection to help impact progressive forms of multiple sclerosis. This chapter discusses currently available disease modifying therapies, agents currently in phase 2/3 trials, and future directions in the treatment of multiple sclerosis.

scholarly journals The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma

2019 ◽  
Vol 92 (1102) ◽  
pp. 20181031 ◽  
Author(s):  
Liang Peng ◽  
Jin-Qi Liu ◽  
Yu-Pei Chen ◽  
Jun Ma
Keyword(s):  
Clinical Trials ◽  
Nasopharyngeal Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Current Treatment ◽  
Treatment Modalities ◽  
Future Research ◽  
Future Directions ◽  
Barr Virus ◽  
The Past ◽  
Epstein Barr

Clinical trials are powerful weapons in the battle against nasopharyngeal carcinoma (NPC). Based on clinical trials conducted in the past two decades, concurrent chemoradiotherapy combined with adjuvant chemotherapy or induction chemotherapy has been recommended as the standard treatment for locoregionally advanced NPC in various guidelines. However, there remain shortcomings concerning current treatment modalities that should be refined in future research. In this article, we review the achievements of published clinical trials for locoregionally advanced NPC and propose future directions for subsequent clinical trials. We believe that refinement of current regimens of chemotherapy, de-intensification of treatment for specific groups of patients, developing personalized treatment based on predictors ( e.g. applying plasma Epstein–Barr virus DNA) and investigating novel therapies, such as targeted therapy and immunotherapy, should be applied with the highest priority when designing clinical trials for locoregionally advanced NPC in the next decade.

Sign in / Sign up

Export Citation Format

Share Document